Health Care
featured
The ASCO meeting scheduled to begin on May 31st could generate a cornucopia of health care catalysts, said Jim Cramer.
» Read More
More
-
I'm thinkin' those two drug giants are champin' at the bit for the docs to get McCain off generic Zocor and onto Lipitor or Crestor. On recent conference calls, some PFE officials have said they think a lot of patients who've had a similar experience to McCain's will eventually come back around to Lipitor.
-
"Forget bartending school, I am going to the school of bud. BTW - as I sit at my desk in pain (played 3 hours of hoops last night and my knees are not happy with me) I wonder, how come Vicodin doesn't come in more than one flavor or variety..."
-
It's generally believed that the number one product from California's number one industry isn't legal. Agriculture remains the Golden State's biggest business, and some believe marijuana is worth $14 billion. No one really knows for sure.
-
My recent post on the new Evista commercial from Eli Lilly elicited a few opinions including one from a woman who says she participated in a focus group for the spot. Laura Bliss says her comments at the time were that the "togas...made the women look like they were already sick....
-
It just keeps getting worse. Pfizer, which is staring down the loss of a $13 billion-a-year drug (Lipitor) in the 2010-11 timeframe, needs the rest of its product portfolio and its drug development pipeline to be firing on all cylinders.
-
New data on Pfizer's Chantix drug to help stop smoking raises new concerns about serious side effects, especially for drivers, pilots and others operating heavy machinery, researchers said on Wednesday.
-
So, Carl Icahn is grabbing headlines this week over his new battle with Yahoo and how Boone Pickens is backing him up now, too. But Icahn has his finger in a lot of pies. He's still in a proxy fight with Biogen Idec where he's trying to get his people on the Board at the upcoming shareholder meeting on June 19th.
-
If sales of Amgen's anemia drugs hadn't fallen so much last year, the American biotechnology industry probably would have turned its first profit in history. That's one of the main conclusions of Ernst & Young's comprehensive annual report on the sector that came out today.
-
Even a tough market and an uncertain economy can't cripple these stocks.
-
Up until last month, AMGN had been atop the list of pharmaceutical manufacturer donors and PFE was in a close second. But the CRP says they flip-flopped in the most recent month that figures are available. So far, in the 2008 election cycle, Pfizer's given $862,000 to candidates and Amgen has forked over $852,000.
-
There's way too much stuff out of ASCO to do a comprehensive blog entry that would satisfy readers--especially small-cap biotechies. I mean, there are literally thousands of pages of research being published today by analysts on the new data.
-
This is gonna be a crazy couple of days. At 9 pm ET tonight the American Society of Clinical Oncology is putting nearly 5,000 studies on its website all at once. Although ASCO says it's all about the science and protecting the "scientific integrity" of its upcoming conference, this is, frankly, an attempt to level the playing field for Wall Street.
-
Two cardiologists write in "The New England Journal of Medicine" that Johnson and Johnson's first-of-its kind TV commercial for a heart stent is aimed at "millions of people who are ill-equipped to make judgments" about the device.
-
I like to think I have a nose for news. And, some might say, too much of a penchant for puns and alliteration. Impotence drug profits won't be going up big pharma's nose. The tiny New Jersey-based biotech company Palatin Technologies says it's giving up on its experimental nasal spray for erectile dysfunction.
-
I realize it's become a bit of a tired tagline, but through the magic of live webcasts what happens in Vegas doesn't stay in Vegas. This morning Dendreon was first at bat at the Bank of America Healthcare Conference in Sin City.
-
So, I admit I watched a lot of television last night and saw a commercial for a relatively new osteoporosis-breast cancer prevention combo drug from Eli Lilly called Evista. Actually, I saw it three times.
-
Occasionally -- when the bosses will let me -- I take a day to network, learn and maybe pick up a story idea by attending a biotech or healthcare investment conference. Many firms put on the events for their clients and they often invite reporters to hang out. ... The PR guy told me a couple of sessions during the day would be "closed" to me. It wasn't clear what the closed sessions were all about, and so my curiousity was piqued...
-
Amgen is in major belt-tightening mode. Still it held its annual shareholder shindig at the swanky Four Seasons Hotel in Westlake Village, CA. The 400-500 investors who showed up were treated to valet parking, soft drinks, and a nice spread of cheeses, vegetable crudite, fruit and sweets
-
One small detail took the stock down Wednesday. Cramer called the CEO to put it in perspective.
-
There's no money left under the pillow, but Amgen execs and directors have been handed a gift. One of the most outspoken, large, individual investors in the biotech company who's been calling for the Board and CEO to go won't be attending its annual shareholder meeting after all.